News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) Chief Touts "Industry-Best" Biosimilars



7/18/2013 7:46:59 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Novartis CEO Joe Jimenez has outlined the firm's determination to be the major force in biosimilars. Speaking as the Swiss major posted its financials for the second quarter (see link), Mr Jimenez (pictured) highlighted the advancement of its biosimilars pipeline. He noted that Novartis' Sandoz unit is running seven Phase III studies across five biosimilar molecules, "more than any other company has in our industry".

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES